Kenalog Age Recommendations
Kenalog (triamcinolone acetonide) can be safely used across all age groups from young children to elderly adults, with specific formulations and dosing adjustments based on age, indication, and route of administration.
Pediatric Use
Intralesional Injection for Infantile Hemangiomas
Intralesional triamcinolone is recommended for focal, bulky infantile hemangiomas during proliferation or in critical anatomic locations 1. The key consideration is avoiding doses exceeding 4 mg/kg to prevent adrenal suppression, which has been infrequently reported at higher doses 1.
Critical safety threshold: Keep doses below 4 mg/kg to minimize risk of:
- Adrenal suppression
- Cushingoid features
- Failure to thrive
- Local skin complications (fat/dermal atrophy, pigmentary changes)
Intranasal Formulation for Allergic Rhinitis
For children aged 2-5 years: Triamcinolone acetonide aqueous nasal spray 110 mcg once daily is effective and safe for perennial allergic rhinitis 2. A 6-month study demonstrated:
- No significant change in serum cortisol levels after cosyntropin stimulation
- Stable stature-for-age percentile distribution
- Comparable adverse event rates to placebo
For children aged 7-12 years: The aerosol formulation can be used up to 440 mcg once daily or in divided doses 3.
Maximum recommended dose for children: 220 mcg once daily for aqueous formulation 3.
Subtenon Injection for Pediatric Uveitis
For children aged 7-18 years: Subtenon triamcinolone 20 mg (0.5 cc) with topical anesthesia alone is well-tolerated in the outpatient setting 4. At 3-month follow-up:
- 85.4% showed improved inflammation
- 77.8% had resolved macular edema
- Significant vision improvement
- 12.5% incidence of ocular hypertension at 6 months
- No immediate complications or new cataracts
Adult Use
Intra-articular Injection for Knee Osteoarthritis
The optimal dose for knee osteoarthritis is 10 mg, which is non-inferior to 40 mg for pain relief 5. This lower dose is preferred because:
- Equivalent pain reduction at 12 weeks
- Similar quality of life improvements
- Potentially reduced cartilage volume loss (40 mg every 3 months for 2 years reduces cartilage volume)
Trigger Finger Treatment
For trigger finger, 20 mg triamcinolone acetonide provides superior outcomes compared to lower doses 6:
- 79% effectiveness at 6 months (vs 62% for 10 mg, 52% for 5 mg)
- Greater VAS pain improvement (4.5 points vs 2.7 for 10 mg, 2.2 for 5 mg)
- Better QuickDASH score improvement (28.9 vs 21.5 for 10 mg, 11.8 for 5 mg)
Subconjunctival Injection for Cataract Surgery
For postoperative inflammation prophylaxis, high-dose TA 10 mg/ml (4 mg total) is optimal 7:
- Lower risk of postoperative macular edema (OR 0.64)
- Similar glaucoma-related event risk compared to topical steroids
- Avoid TA 40 mg/ml high-dose formulation (increased glaucoma risk: OR 2.14)
Elderly Use
Intramuscular Injection for Severe Asthma
For elderly patients with severe, chronic, steroid-dependent asthma, high-dose intramuscular triamcinolone 360 mg can be considered 8. In 7 elderly patients:
- Resolution of symptoms within 1 week
- Marked functional improvement (6 of 7 progressed from homebound to independent)
- Peak expiratory flow rate increases of 25-93%
- All discontinued daily oral prednisone
- Response duration: 3-24 months
Important caveats:
- Transient weakness and diabetes may occur during first week
- Reserve for highly select, steroid-dependent patients
- Patients should be counseled about temporary metabolic effects
Key Clinical Pitfalls
Pediatric adrenal suppression: Never exceed 4 mg/kg for intralesional injections 1
Cartilage damage: Avoid repeated high-dose (40 mg) intra-articular injections every 3 months; use 10 mg instead 5
Ocular complications: For periocular injections, avoid high injection pressures/volumes to prevent central retinal artery embolization 1
Growth monitoring: For intranasal use >12 months in children, monitor growth every 3 months 3
Formulation-specific dosing: TA 10 mg/ml and 40 mg/ml are NOT interchangeable—the 40 mg/ml formulation carries higher glaucoma risk in ophthalmic use 7